THIS ANNOUNCEMENT AND THE INFORMATION IN IT, IS RESTRICTED AND IS NOT FOR PUBLICATION, RELEASE OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, THE REPUBLIC OF SOUTH AFRICA, JAPAN, NEW ZEALAND, SINGAPORE OR ANY OTHER JURISDICTION IN WHICH SUCH PUBLICATION, RELEASE OR DISTRIBUTION WOULD BE UNLAWFUL.

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF EU REGULATION 596/2014 (WHICH FORMS PART OF DOMESTIC UK LAW PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ACT 2018 ("EUWA")) ("UK MAR"). IN ADDITION, MARKET SOUNDINGS (AS DEFINED IN UK MAR) WERE TAKEN IN RESPECT OF CERTAIN OF THE MATTERS CONTAINED WITHIN THIS ANNOUNCEMENT, WITH THE RESULT THAT CERTAIN PERSONS BECAME AWARE OF INSIDE INFORMATION (AS DEFINED UNDER UK MAR). UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THOSE PERSONS WHO RECEIVED INSIDE INFORMATION IN A MARKET SOUNDING ARE NO LONGER IN POSSESSION OF SUCH INSIDE INFORMATION, WHICH IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.

22 May 2025

Nuformix plc

("Nuformix" or the "Company" or the "Group")

£210,000 Placing

Nuformix plc (LSE:NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, announces a conditional placing (the "Placing") to raise gross proceeds of £210,000 through the issue of 300,000,000 new ordinary shares ("New Ordinary Shares") in the capital of the Company at a price of 0.07 pence per share (the "Issue Price").

The net proceeds of the Placing will be used by the Company to drive forward partnering discussions for its NXP002 programme, an inhaled treatment for idiopathic pulmonary fibrosis ("IPF") and progressive pulmonary fibrosis ("PPF"), as well as to provide funding to enable the submission of an application for Orphan Drug Designation in the USA for NXP002 in the treatment of IPF, and for general corporate purposes.

The Placing and issue of the New Ordinary Shares are subject to the fulfilment of the following conditions ("Conditions"): (i) approval by the Financial Conduct Authority ("FCA") and publication by the Company of a prospectus; (ii) there being no breach of the obligations under the placing agreement entered into between CMC Markets UK Plc ("CMC Markets") and the Company prior to Admission; and (iii) admission of the New Ordinary Shares to trading on the Main Market of the London Stock Exchange ("Admission") becoming effective. 

Application will be made to the London Stock Exchange for the New Ordinary Shares to be admitted to trading on the Main Market of the London Stock Exchange and the equity shares (transition) category the FCA Official List assuming the Conditions are met.

The Company and its advisers are finalising the prospectus and, following FCA approval, anticipate being able to release a further update regarding the timetable for Admission.

CMC Markets trading as CMC CapX, acted as the Company's sole placing agent in respect of the Placing.

Commenting, Dr Dan Gooding, Executive Director of Nuformix, said: "The Placing will provide the Company with additional funds to support it through an exciting period as we progress discussions with potential licensing and development partners, who like us are keen to improve the treatment of IPF and PPF via inhalation.  Following the news of the European Medicines Agency's Committee for Orphan Medicinal Products positive opinion regarding NXP002's eligibility for Orphan Drug Designation in IPF we will now also be applying for US FDA orphan drug designation. I look forward to providing further updates in due course."

Enquiries:

About Nuformix

Nuformix is a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing. The Company aims to use its expertise in discovering, developing and patenting novel drug forms, with improved physical properties, to develop new products in new indications that are, importantly, differentiated from the original (by way of dosage, delivery route or presentation), thus creating new and attractive commercial opportunities. Nuformix has a pipeline of preclinical assets with potential for significant value and early licensing opportunities.